Furthermore, we demonstrated that recombinant FGF21 reduced the PCB-induced overexpression of hepatic LCN2 in both in vivo and in vitro NAFLD/NASH models. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.